Asia Pacific Cell Culture Media Market Size & Outlook
Asia Pacific cell culture media market, 2018-2030 (US$M)
Related Markets
Asia Pacific cell culture media market highlights
- The Asia Pacific cell culture media market generated a revenue of USD 1,242.7 million in 2023.
- The market is expected to grow at a CAGR of 14.5% from 2024 to 2030.
- In terms of segment, serum-free media was the largest revenue generating product in 2023.
- Serum-free Media is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,242.7 million |
| Market revenue in 2030 | USD 3,213.9 million |
| Growth rate | 14.5% (CAGR from 2023 to 2030) |
| Largest segment | Serum-free media |
| Fastest growing segment | Serum-free Media |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Serum-free Media, Classical Media, Stem Cell Culture Media, Chemically Defined Media, Specialty Media, Other Cell Culture Media |
| Key market players worldwide | Sartorius AG, Danaher Corp, Merck KGaA, Thermo Fisher Scientific Inc, FUJIFILM Holdings Corp, Lonza Group Ltd, BD, STEMCELL Technologies, PromoCell GmbH |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 26.3% of the global cell culture media market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,213.9 million by 2030.
Serum-free media was the largest segment with a revenue share of 34.98% in 2023. Horizon Databook has segmented the Asia Pacific cell culture media market based on serum-free media, classical media, stem cell culture media, chemically defined media, specialty media, other cell culture media covering the revenue growth of each sub-segment from 2018 to 2030.
In the next 5 years, China aims to become a leading nation in biotechnology. The Chinese government is projected to have spent more than USD 100 billion on life sciences research and development over the past 5 years. Beijing is a lucrative market with a variety of financial incentives as state-backed organizations provide generous grants to innovative entrepreneurs, further demonstrating its efforts.
The Biosafety Law came into effect on April 15, 2021, the 6th National Security Education Day in China, establishing a thorough, organized, and overarching legal framework for this crucial field. The recent 33rd Politburo combined study sitting of the CPC Central Committee focused on strengthening China's biosafety laws to emphasize its rising significance. The Biosafety Law categorizes biotechnology R&D as high, medium, and low risks. The competent authorities will develop, amend, and publish particular categorization criteria and lists when the legislation is introduced.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Culture Media Market Scope
Cell Culture Media Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cell culture media market size, by country, 2018-2030 (US$M)
Asia Pacific Cell Culture Media Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
